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Introduction: Angelman syndrome, a neurodevelopmental genetic disorder associated with abnormalities in
chromosome15q11-q13, is inherited from the mother. Epilepsy is seen in 85 % of children with Angelman syndrome
within the first 3 years of life and is often severe and difficult to control.
Case presentation: We report a case of a baby boy who presented at 13 months of age with a history of acute
gastroenteritis and marked gross motor and speech developmental delay. He was found to have a microdeletion
of the chromosome 15q11.2 region confirming the diagnosis of Angelman syndrome. He was the first child born
to healthy, unrelated Sinhalese parents. The child had generalized extensor spasms involving both upper limbs and
the head beginning at the age of 9 months, and he developed flexor and extensor spasms at the age of 13 months. His
facial appearance was characteristic of Angelman syndrome. His electroencephalographic pattern did not correspond to
any other of the patterns previously described in patients with Angelman syndrome. He had extensor and flexor spasms,
which are rarely described in patients with Angelman syndrome. These symptoms responded to a combination of
valproic acid and clonazepam.
Conclusions: Angelman syndrome due to a microdeletion of the chromosome 15q11.2 region is often not diagnosed
in infancy. Extensor and flexor spasms are not typically described seizure types in Angelman syndrome, and our patient’s
seizures responded well to a combination of valproic acid and clonazepam. Clinicians should suspect other possible
seizure types in patients with Angelman syndrome and should treat the patient appropriately.
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Angelman syndrome (AS), a neurodevelopmental genetic
disorder associated with abnormalities in chromosome
15q11-q13, is inherited from the mother. These abnormal-
ities are a de novo interstitial deletion of 15q11-q13 (70 %
to 75 % of patients), maternal uniparental disomy of
chromosome 15 (2 % of patients), imprinting center muta-
tions (2 % of patients) and mutations in ubiquitin protein
ligase E3A gene, UBE3A (5 % of patients). In 10 % of
patients with AS, the genetic etiology is unidentified [1].
The condition is now increasingly being diagnosed
worldwide because of improvement of diagnostic tests [2].* Correspondence: c.ranasinghe0323@gmail.com
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creativecommons.org/publicdomain/zero/1.0/The estimated incidence of AS ranges from 1 in 10,000 to
1 in 40,000 in different populations [3].
Epilepsy is seen in 85 % of children with AS within the
first 3 years of life and is often severe and difficult to
control [4]. Different types of seizures and four charac-
teristic electroencephalographic (EEG) patterns have
been described in patients with AS [5].Case presentation
A 13-month-old baby boy was presented to our hospital
with a history of acute gastroenteritis and marked gross
motor and speech developmental delay. He was the first
child born to healthy, unrelated Sinhalese parents. The
mother was 23 years old, and the father was 21 years old.
The mother noted the child having abnormal movementsss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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age, the description of which resembled generalized exten-
sor spasms. There was clustering of similar events and
sleep deprivation, which were compatible with seizures,
from that age onward.
The initial generalized extensor spasms involving both
upper limbs and the head, occurring as short-lasting
clusters (one spasm would persist for about 1 to 2 sec-
onds, with recurrence in 10 to 20 clustering events, each
occurrence lasting for about 3 to 5 minutes), transformed
by the age of 1 year and 2 months into spasms of a flexor
type resembling infantile spasms. Subsequently, the child
developed generalized tonic-clonic convulsions. Most of
the time, the seizures were precipitated by a low-grade
fever, leading to repeated hospital admissions. The focus
for the recurrent fever was not identified.
The seizures could not be controlled with valproic acid
(VPA) (30mg/kg body weight/day) alone for 1 month
and in combination with carbamazepine (CBZ) (5mg/
kg body weight/day) for 2 weeks. VPA administered to-
gether with clonazepam (CNZ) (0.5mg/kg body weight/
day), after omission of CBZ, proved to be effective, and
the child remained seizure-free for 4 months. There were
no early side effects of the drugs noted at a follow-up
examination.
A physical examination revealed that the child had
marked hypotonia with characteristic facial appearance
of deep-set eyes, a wide mouth with protruding tongue
and a pointed nose resembling AS. He is fair in com-
plexion, with a hypopigmented patch over the left
anterior thigh. Characteristically, he keeps his hands
upheld, and he exhibits abnormal, uncoordinated, jerky
movements of the arms. He always tends be seated withFig. 1 Electroencephalogram obtained when the patient was 13 months o
of diffuse, moderate-amplitude, polymorphic delta activities alternating with aa rounded back, suggestive of underlying scoliosis, and
he has episodes of inappropriate laughter. His teeth
had not yet erupted, and he had marked developmental
delay affecting all components. When he presented to
our hospital at the age of 13 months, all developmental
parameters resembled those of a child between 7 and 8
months of age. Monosyllabic babbling had started at
the age of 1 year. After 4 months of treatments, he
showed marked improvement. There were no seizures.
He was able to sit without support and able to keep his
back straight. He was stable in standing position with
support for a very short period (<5s). He had weight
gain. The abnormalities observed on the first EEG tra-
cing (Fig. 1) were not characteristic of AS. The sleep
background was immature and comprised of blocks of
diffuse, moderate-amplitude, polymorphic delta activities
alternating with a delta-theta mixed background. No epi-
leptiform discharges were seen. Repeat EEG scan (Fig. 2)
done after 2 months of treatment revealed a normal sleep
EEG scan with age-matched background with symmetric
sleep spindles, as well as a few K complexes. Excess diffuse
fast activity could likely be a CNZ-induced phenomenon.
Computed tomography of the brain showed prominent
sulci with widened subarachnoid spaces bilaterally in the
frontal region, and a few hypodense areas were seen in the
frontal white matter, predominantly in the periventricular
region and centrum semiovale. Furthermore, there was
mild prominence in the ventricular system favoring early
cerebral atrophy.
His karyotype at 500-band resolution was that of a
normal male (46,XY). Microdeletion testing by multiplex
ligation probe amplification (MLPA) using the SALSA®
MLPA® P290-B2 Prenatal Deletions probemix (MRC-f age. We noted an immature sleep background composed of blocks
delta-theta mixed background. No epileptiform discharges were observed
Fig. 2 Normal sleep electroencephalogram after 2 months of treatment, with age-matched background with symmetric sleep spindles and a few
K complexes. Excess diffuse fast activity could likely be a clonazepam-induced phenomenon
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manufacturer’s protocol showed the presence of a deletion
involving all the probes for the 15q11.2 region.Discussion
AS was first described in three unrelated children as
“happy puppet” syndrome by English pediatrician Harry
Angelman in 1965 [6]. Later, in 1982, Williams and Frias
documented the natural history of AS [7].
Characteristic features of AS are frequent paroxysms
of laughter, abnormal puppet-like gait, ataxia, character-
istic facies, intellectual disability, seizures, sleep distur-
bances and a characteristic behavioral profile with delay
in developmental milestones with learning disabilities
and language impairment [2, 3, 6, 7]. The majority of
patients with AS experience some form of seizures dur-
ing their lifetime. Confirmation of the diagnosis during
infancy is not common [8].
Flexion and tonic extension-type seizures are rarely
described in AS. The most frequent types of seizures are
atypical absence, generalized tonic-clonic, atonic and
myoclonic seizures. In a series of 35 patients described
by Galván-Manso and colleagues, only 6 (17 %) had
extensor spasms and 2 (6 %) had flexion-type seizures
[9]. Of patients with 15q11-q13 deletion, 50 % experi-
enced atypical absence, generalized tonic-clonic, atonic
or myoclonic seizures [8]. Although only 25 % develop
seizures in the first year of life [10], the majority (85 %)
develop seizures by the age of 3 years [4]. Early diagnosis
and treatment of seizures in our patient were achieved,
with successful control of seizures and improved devel-
opmental milestones over a period of 4 months. This
observation about AS is new, because the majority (85 %)of cases present in later life and the seizures are difficult
to control [4]. Early genetic confirmation helps in success-
ful management.
Patients with a chromosome 15q11.2 deletion experi-
ence intellectual disability, speech and language delay,
motor delay, autistic spectrum disorder, epilepsy and
schizophrenia [11]. There are a significant number of
patients with idiopathic generalized epilepsy who have
subsequently been confirmed to have a chromosome
15q11.2 deletion [12].
In 1988, three EEG patterns were described in a patient
with AS by Boyd and colleagues [13]. In 2003, four EEG
patterns were described by Valente and co-workers (a
hypsarrhythmia-like variant; an ill-defined, slow, spike-
and-wave variant; a triphasic–like variant; and a slow vari-
ant) [5]. Our patient, however, did not show any of these
EEG patterns.
VPA and CNZ can effectively control seizures in pa-
tients with AS when these agents are used as mono-
therapy. Some patients, however, require a combination
of VPA and CNZ or VPA and clobazam [8, 11].
Our patient’s seizures were controlled poorly with CBZ.
A subsequent change to a combination of VPA and CNZ
resulted in good seizure control.Conclusions
AS due to a microdeletion of chromosome 15q11.2 region
is often not diagnosed in infancy. Extensor and flexor
spasms are not typically described seizure types in AS, and
our patient’s seizures responded well to a combination
of VPA and CNZ. Even though there were characteristic
EEG patterns, his EEG scans did not correspond to any of
the EEG patterns described previously in AS. However, in
Ranasinghe et al. Journal of Medical Case Reports  (2015) 9:142 Page 4 of 4a patient with AS, other EEG patterns also should be
considered. Clinicians should suspect other possible
seizure types in patients with AS and should treat them
appropriately.
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